(VIANEWS) – Consolidated Water Co. Ltd. (CWCO), Genmab (GMAB), Medallion Financial Corp. (MFIN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Consolidated Water Co. Ltd. (CWCO)
48.7% sales growth and 13.56% return on equity
Consolidated Water Co. Ltd., together with its subsidiaries, designs, constructs, manages, and operates water production and water treatment plants primarily in the Cayman Islands, the Bahamas, and the United States. The company operates through four segments: Retail, Bulk, Services, and Manufacturing. It uses reverse osmosis technology to produce potable water from seawater. The company produces and supplies water to end-users, including residential, commercial, and government customers, as well as government-owned distributors. It also provides design, engineering, construction, procurement, and management services for desalination projects and water treatment plants, as well as management and engineering services relating to municipal water distribution and treatment. In addition, the company manufactures and services a range of water-related products, including reverse osmosis desalination equipment, membrane separation equipment, filtration equipment, piping systems, vessels, and custom fabricated components; and provides design, engineering, consulting, management, inspection, training, and equipment maintenance services for commercial, municipal, and industrial water production, supply, and treatment, as well as desalination and wastewater treatment. Consolidated Water Co. Ltd. was incorporated in 1973 and is headquartered in Grand Cayman, the Cayman Islands.
Earnings Per Share
As for profitability, Consolidated Water Co. Ltd. has a trailing twelve months EPS of $1.44.
PE Ratio
Consolidated Water Co. Ltd. has a trailing twelve months price to earnings ratio of 23.97. Meaning, the purchaser of the share is investing $23.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.56%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Consolidated Water Co. Ltd.’s EBITDA is 3.2.
Revenue Growth
Year-on-year quarterly revenue growth grew by 99%, now sitting on 155.39M for the twelve trailing months.
Previous days news about Consolidated Water Co. Ltd.(CWCO)
- According to Zacks on Wednesday, 29 November, "A few other top-ranked stocks from the same industry are Global Water Resources (GWRS Quick QuoteGWRS – Free Report) , The York Water Company (YORW Quick QuoteYORW – Free Report) and Consolidated Water Co. Ltd. "
2. Genmab (GMAB)
40.6% sales growth and 14.87% return on equity
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $0.96.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 32.99. Meaning, the purchaser of the share is investing $32.99 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.87%.
3. Medallion Financial Corp. (MFIN)
35.6% sales growth and 15.82% return on equity
Medallion Financial Corp., together with its subsidiaries, operates as a finance company in the United States. The company operates through four segments: Recreation Lending, Home Improvement Lending, Commercial Lending, and Medallion Lending. It provides loans that finance consumer purchases of recreational vehicles, boats, and trailers; consumer home improvements; commercial businesses; and taxi medallions to individuals, and small to mid-size businesses. The company also offers commercial loans for purchase of equipment and related assets necessary to open a new business, or purchase or improvement of an existing business; and medallion loans. In addition, it provides debt, mezzanine, and equity investment capital to companies in various industries; and raises deposits and conducts other banking activities. Medallion Financial Corp. was incorporated in 1995 and is headquartered in New York City, New York.
Earnings Per Share
As for profitability, Medallion Financial Corp. has a trailing twelve months EPS of $2.34.
PE Ratio
Medallion Financial Corp. has a trailing twelve months price to earnings ratio of 4.03. Meaning, the purchaser of the share is investing $4.03 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.82%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Nov 13, 2023, the estimated forward annual dividend rate is 0.4 and the estimated forward annual dividend yield is 4.24%.
Sales Growth
Medallion Financial Corp.’s sales growth is 14.5% for the ongoing quarter and 35.6% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 36.2%, now sitting on 247.52M for the twelve trailing months.
4. Merchants Bancorp (MBIN)
16.4% sales growth and 17% return on equity
Merchants Bancorp operates as the diversified bank holding company in the United States. It operates through Multi-family Mortgage Banking, Mortgage Warehousing, and Banking segments. The Multi-family Mortgage Banking segment engages in the mortgage banking, which originates and services government sponsored mortgages including bridge financing products to refinance, acquire, or reposition multi-family housing projects, and construction lending for multi-family and healthcare facilities; offers customized loan products for need-based skilled nursing facilities, independent living, assisted living, and memory care; and tax credit equity syndicator. Its Mortgage Warehousing segment funds agency eligible residential loans including origination, purchase, and sale in the secondary market, as well as commercial loans to non-depository financial institutions. The Banking segment offers a range of financial products and services to consumers and businesses, which includes retail banking, commercial lending, agricultural lending, retail and correspondent residential mortgage banking, and small business administration lending. Merchants Bancorp was founded in 1990 and is headquartered in Carmel, Indiana.
Earnings Per Share
As for profitability, Merchants Bancorp has a trailing twelve months EPS of $5.17.
PE Ratio
Merchants Bancorp has a trailing twelve months price to earnings ratio of 6.36. Meaning, the purchaser of the share is investing $6.36 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17%.
Volume
Today’s last reported volume for Merchants Bancorp is 62516 which is 26.13% below its average volume of 84638.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 28.6% and 27.1%, respectively.
Previous days news about Merchants Bancorp(MBIN)
- According to Zacks on Thursday, 30 November, "Some better-ranked stocks in the Finance space are Federal Agricultural Mortgage Corporation (AGM Quick QuoteAGM – Free Report) and Merchants Bancorp (MBIN Quick QuoteMBIN – Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. ", "Shares of Federal Agricultural Mortgage and Merchants Bancorp have gained 22.7% and 47.7%, respectively, in the past six months."
5. Gilat Satellite Networks Ltd. (GILT)
10.1% sales growth and 5.46% return on equity
Gilat Satellite Networks Ltd., together with its subsidiaries, provides satellite-based broadband communication solutions in Israel and internationally. It operates through Fixed Networks, Mobility Solutions, and Terrestrial Infrastructure Projects segments. The company designs and manufactures ground-based satellite communications equipment; and provides solutions and end-to-end services. Its portfolio consists of very small aperture terminals, amplifiers, modems, on-the-move antennas, solid state power amplifiers, block upconverters, transceivers, low-profile antennas, and on-the-move/on-the-pause terminals and modems. The company also offers turnkey integrated solutions, including managed satellite network services, network planning and optimization, satellite capacity, remote network operation, call center support, hub and field operations, and communication networks construction and installation services. In addition, it provides connectivity services, Internet access, and telephony services to enterprise, government, and residential customers; and builds telecommunication infrastructure using fiber-optic and wireless technologies for broadband connectivity. The company sells its products and solutions to communication service providers, satellite operators, governments, mobile network operators, telecommunication companies, and system integrators, as well as to defense and homeland security organizations, and directly to end-users. Gilat Satellite Networks Ltd. was incorporated in 1987 and is headquartered in Petah Tikva, Israel.
Earnings Per Share
As for profitability, Gilat Satellite Networks Ltd. has a trailing twelve months EPS of $0.24.
PE Ratio
Gilat Satellite Networks Ltd. has a trailing twelve months price to earnings ratio of 26.25. Meaning, the purchaser of the share is investing $26.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.46%.
Sales Growth
Gilat Satellite Networks Ltd.’s sales growth is 4.8% for the current quarter and 10.1% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Gilat Satellite Networks Ltd.’s EBITDA is 1.01.
6. FirstCash (FCFS)
9.2% sales growth and 12.35% return on equity
FirstCash Holdings, Inc, together with its subsidiaries, operates retail pawn stores in the United States, Mexico, and rest of Latin America. Its pawn stores lend money on the collateral of pledged personal property, including jewelry, electronics, tools, appliances, sporting goods, and musical instruments; and retails merchandise acquired through collateral forfeitures on forfeited pawn loans and over-the-counter purchases of merchandise directly from customers. The company is also involved in melting scrap jewelry, as well as sells gold, silver, and diamonds in commodity markets. As of December 31, 2021, it operated 1,081 stores in the United States and the District of Columbia; 1,656 stores in Mexico; 60 stores in Guatemala; 13 stores in El Salvador; and 15 stores in Colombia. The company was incorporated in 1988 and is headquartered in Fort Worth, Texas.
Earnings Per Share
As for profitability, FirstCash has a trailing twelve months EPS of $4.99.
PE Ratio
FirstCash has a trailing twelve months price to earnings ratio of 22.41. Meaning, the purchaser of the share is investing $22.41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.35%.
Sales Growth
FirstCash’s sales growth is 13.7% for the current quarter and 9.2% for the next.
Moving Average
FirstCash’s value is above its 50-day moving average of $102.74 and way higher than its 200-day moving average of $96.62.
Previous days news about FirstCash(FCFS)
- According to Zacks on Thursday, 30 November, "The bottom line of FirstCash outpaced estimates in each of the last four quarters, the average surprise being 7.86%. ", "While FirstCash sports a Zacks Rank #1 (Strong Buy), Brink’s and FTI Consulting carry a Zacks Rank #2 (Buy) at present. "
- According to Zacks on Friday, 1 December, "In contrast, FirstCash Holdings falls under the Financial Transaction Services industry. ", "For FirstCash Holdings, the consensus EPS estimate for the current year has increased 5.9% over the past three months. "
7. Copa Holdings, S.A. Copa Holdings, S.A. (CPA)
7.2% sales growth and 24.37% return on equity
Copa Holdings, S.A., through its subsidiaries, provides airline passenger and cargo services. The company offers approximately 104 daily scheduled flights to 54 destinations in 25 countries in North, Central, and South America, as well as the Caribbean from its Panama City hub. As of December 31, 2020, it operated a fleet of 77 aircraft comprising 70 Boeing 737-Next Generation aircraft and 7 Boeing 737 MAX 9 aircraft. Copa Holdings, S.A. was founded in 1947 and is based in Panama City, Panama.
Earnings Per Share
As for profitability, Copa Holdings, S.A. Copa Holdings, S.A. has a trailing twelve months EPS of $9.7.
PE Ratio
Copa Holdings, S.A. Copa Holdings, S.A. has a trailing twelve months price to earnings ratio of 9.7. Meaning, the purchaser of the share is investing $9.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.37%.
Yearly Top and Bottom Value
Copa Holdings, S.A. Copa Holdings, S.A.’s stock is valued at $94.11 at 00:22 EST, way under its 52-week high of $121.20 and way higher than its 52-week low of $78.12.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Copa Holdings, S.A. Copa Holdings, S.A.’s EBITDA is 1.33.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.2%, now sitting on 3.43B for the twelve trailing months.
8. Bruker Corporation (BRKR)
5.8% sales growth and 29.32% return on equity
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Earnings Per Share
As for profitability, Bruker Corporation has a trailing twelve months EPS of $2.16.
PE Ratio
Bruker Corporation has a trailing twelve months price to earnings ratio of 28.37. Meaning, the purchaser of the share is investing $28.37 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.32%.
Moving Average
Bruker Corporation’s value is higher than its 50-day moving average of $60.99 and way under its 200-day moving average of $70.00.
Yearly Top and Bottom Value
Bruker Corporation’s stock is valued at $61.28 at 00:22 EST, way below its 52-week high of $84.84 and way higher than its 52-week low of $53.79.
Previous days news about Bruker Corporation(BRKR)
- According to Zacks on Wednesday, 29 November, "Accelerate Diagnostics, Inc. (AXDX Quick QuoteAXDX – Free Report) has initiated a collaboration and quality agreement with Bruker Corporation (BRKR Quick QuoteBRKR – Free Report) . "
